Figure 7 European Society of Cardiology 2016

Slides:

Advertisements

Similar presentations

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 by, John J.V. McMurray, Stamatis Adamopoulos, Stefan D. Anker, Angelo.

Advertisements

To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.

Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment.

Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians by Willem J. Remme, John.

To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE PATIENT QUALITY OF LIFE STATISTICS.

Acute viral myocarditis by Robert Dennert, Harry J. Crijns, and Stephane Heymans EHJ Volume 29(17): August 25, 2008 Published on behalf of the.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 by , Kenneth Dickstein, Alain Cohen-Solal, Gerasimos Filippatos,

Dronedarone in patients with congestive heart failure: insights from ATHENA by Stefan H. Hohnloser, Harry J.G.M. Crijns, Martin van Eickels, Christophe.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Figure 1 Initial management of a patient with acute heart failure

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

<sup>d</sup>Stands for as long as it is well tolerated.

Figure 1 Representative longitudinal strain analysis in an apical two-chamber view. The view is presented in the left panel and the longitudinal strain.

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Diagnostic flowchart for patients with suspected heart failure—showing alternative ‘echocardiography first’ (blue) or ‘natriuretic peptide first’

From: Where do we go from here

American College of Cardiology Foundation/American Heart Association 2009 heart failure staging guidelines. CHF, congestive heart failure; CM, cardiomyopathy;

Figure 1 Study flow chart

Figure 1 Anatomy of the spinal column

Reproduced with permission from Yancy, C. W. et al. 2017

Figure 8 Implanted devices for the management of heart failure

Diabetes Mellitus and Heart Failure

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Cardiol. doi: /nrcardio

Date of download: 2/22/2017 © The European Society of Cardiology All rights reserved. For permissions please

Figure 8 HRQOL in individuals with RA

Figure 1 Study flow diagram and definition of clinical response

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Adapted with permission from Tesfaye, S. , Boulton, A. J

Figure 1 Mechanism of mortality benefit associated with radial access

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Editorial Heart Failure Clinics

Figure 9 Management of atrial fibrillation

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Take home figure The protective role of CNP/NPR-B/NPRC.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Take home figure The 38% of heart failure reduced ejection fraction (HFrEF) patients who recovered LVEF (HFrecEF) were more ... Take home figure The 38%

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Immunohistochemistry for human cell differentiation molecules in samples of the right ventricular septum from ... Figure 1 Immunohistochemistry.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure Ranking of Cardiovascular Journals as published by Clarivate Analytics. Unless provided in the caption above, the following copyright applies.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 4 Treponema pallidum invasion

Figure 1 Patient selection.

Figure 5 Algorithm for the management of hypertension

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Figure 1 Treponema pallidum

Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Figure 4 Clinical manifestations of alopecia areata

Figure 1 ABCDE of primary prevention.2

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Figure 7 European Society of Cardiology 2016 guidelines for the treatment of patients with symptomatic HFrEF Reproduced from Ponikowski, P., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37 (27): 2129–2200. doi: 10.1093/eurheartj/ehw128,. Reproduced with permission of Oxford University Press on behalf of the European Society of Cardiology. Please visit: www.escardio.org Bloom, M. W. et al. (2017) Heart failure with reduced ejection fraction Nat. Rev. Dis. Primers doi:10.1038/nrdp.2017.58